NICOX SA (COX.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:COX - FR0013018124 - Common Stock
COX.PA Key Statistics, Chart & Performance
The current stock price of COX.PA is 0.579 EUR. In the past month the price decreased by -8.1%. In the past year, price decreased by -66.14%.
COX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 68.41 | 44.56B | ||
| 1AE.DE | ARGENX SE | 67.67 | 44.08B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.80B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.39B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.93B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.85B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.86B | ||
| NANO.PA | NANOBIOTIX | N/A | 918.99M | ||
| 5CV.DE | CUREVAC NV | 6.24 | 815.12M | ||
| IVA.PA | INVENTIVA SA | N/A | 770.76M | ||
| PHIL.MI | PHILOGEN SPA | 20.44 | 681.29M | ||
| FYB.DE | FORMYCON AG | N/A | 455.89M |
Related stock screener links
About COX.PA
Company Profile
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Company Info
NICOX SA
Drakkar 2 - Batiment D, 2405 route des Dolines, CS 10313 Sophia Antipolis
Valbonne PACA FR
Employees: 32
Phone: 33497245300.0
NICOX SA / COX.PA FAQ
What does NICOX SA do?
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
What is the stock price of NICOX SA today?
The current stock price of COX.PA is 0.579 EUR. The price decreased by -0.52% in the last trading session.
Does NICOX SA pay dividends?
COX.PA does not pay a dividend.
How is the ChartMill rating for NICOX SA?
COX.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for NICOX SA?
NICOX SA (COX.PA) operates in the Health Care sector and the Biotechnology industry.
Would investing in NICOX SA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on COX.PA.
Can you provide the market cap for NICOX SA?
NICOX SA (COX.PA) has a market capitalization of 28.92M EUR. This makes COX.PA a Nano Cap stock.
COX.PA Technical Analysis
COX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COX.PA. COX.PA may be in some trouble as it scores bad on both profitability and health.
COX.PA Financial Highlights
Over the last trailing twelve months COX.PA reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 47.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.47 |
COX.PA Forecast & Estimates
8 analysts have analysed COX.PA and the average price target is 2.91 EUR. This implies a price increase of 402.07% is expected in the next year compared to the current price of 0.579.
For the next year, analysts expect an EPS growth of 35.92% and a revenue growth 16.23% for COX.PA